Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 18, 2026 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
February 03, 2026 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis

aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
November 10, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference

aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference
November 06, 2025 16:01 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update
September 30, 2025 05:30 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025

aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society Congress 2025
September 15, 2025 07:30 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
September 05, 2025 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2025 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update

aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update
July 22, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
June 26, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes